alexa Center of Excellence in Biomaterials and Tissue Engineering (BIOMATEN)

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Center of Excellence in Biomaterials and Tissue Engineering (BIOMATEN)

In 2010 BIOMATEN, the “Center of Excellence in Biomaterials and Tissue Engineering” was established at METU with a grant supported by the Ministry of Development (formerly the State Planning Organization). In the same year, the “Biomaterials and Tissue Engineering Application and Research Center” was established. The two centers share the acronym “BIOMATEN” and have the same goals and functions. BIOMATEN has members from the Departments of Biological Sciences, Chemistry, Mechanical Engineering, Metallurgical and Material Engineering, Engineering Sciences, and Biotechnology of METU. Center of Excellence has a broader membership profile in addition to academic members from METU. There are also members from Hacettepe, Yeditepe, Kocaeli, Ä°TÜ, Çukurova and Acıbadem Universities. Professors from world famous universities from the USA (Harvard, MIT, Drexel, and Tufts), Germany (Johannes Gutenberg) and UK (London) are also supporting us as our International Advisory Board. In addition, “Biomaterials and Tissue Engineering Society of Turkey”, established in 2008, is one of the non-governmental organizations that support the centers. BIOMATEN aims to become a national and international reference and counselling point, to be able to consult and guide the state institutions that make decisions and financially support projects, medical industrialists, young and expert researchers. BIOMATEN also wish to support the medical sector in the development and production of high added value products, and to characterize and certify medical products. BIOMATEN plans to get the first products through clinical trials and to the markets by 2014.

adwords